Tags

Type your tag names separated by a space and hit enter

The use of gamma-linolenic acid in diabetic neuropathy.
Agents Actions Suppl 1992; 37:120-44AA

Abstract

EF4 is an entirely new approach to the management of diabetic neuropathy. EF4 (providing gamma-linolenic acid or gamolenic acid, GLA) has been shown to reverse existing diabetic neuropathy in trials in seven centres. Diabetic animals and humans have a reduced ability to convert dietary linoleic acid to GLA. GLA and its metabolites are required for normal neuronal structure and function and a normal microcirculation. The lack of GLA and its metabolites may play a major role in the development of the neuropathy. EF4 helps to correct the biochemical defects, restores levels of GLA metabolites towards normal and produces highly significant clinical and neurophysiological improvements in diabetic neuropathy.

Authors+Show Affiliations

Efamol Research Institute, Kentville, Nova Scotia, Canada.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

1321553

Citation

Horrobin, D F.. "The Use of Gamma-linolenic Acid in Diabetic Neuropathy." Agents and Actions. Supplements, vol. 37, 1992, pp. 120-44.
Horrobin DF. The use of gamma-linolenic acid in diabetic neuropathy. Agents Actions Suppl. 1992;37:120-44.
Horrobin, D. F. (1992). The use of gamma-linolenic acid in diabetic neuropathy. Agents and Actions. Supplements, 37, pp. 120-44.
Horrobin DF. The Use of Gamma-linolenic Acid in Diabetic Neuropathy. Agents Actions Suppl. 1992;37:120-44. PubMed PMID: 1321553.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The use of gamma-linolenic acid in diabetic neuropathy. A1 - Horrobin,D F, PY - 1992/1/1/pubmed PY - 1992/1/1/medline PY - 1992/1/1/entrez SP - 120 EP - 44 JF - Agents and actions. Supplements JO - Agents Actions Suppl. VL - 37 N2 - EF4 is an entirely new approach to the management of diabetic neuropathy. EF4 (providing gamma-linolenic acid or gamolenic acid, GLA) has been shown to reverse existing diabetic neuropathy in trials in seven centres. Diabetic animals and humans have a reduced ability to convert dietary linoleic acid to GLA. GLA and its metabolites are required for normal neuronal structure and function and a normal microcirculation. The lack of GLA and its metabolites may play a major role in the development of the neuropathy. EF4 helps to correct the biochemical defects, restores levels of GLA metabolites towards normal and produces highly significant clinical and neurophysiological improvements in diabetic neuropathy. SN - 0379-0363 UR - https://www.unboundmedicine.com/medline/citation/1321553/The_use_of_gamma_linolenic_acid_in_diabetic_neuropathy_ L2 - https://medlineplus.gov/diabeticnerveproblems.html DB - PRIME DP - Unbound Medicine ER -